Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need

By Pharmaceutical Processing | September 28, 2010

Pfizer Inc. has provided an update to
its development pipeline, which includes 118 programs from Phase 1 through
registration. The updated pipeline continues to reflect Pfizer’s ongoing
investment in high-priority disease areas with considerable unmet medical need.

“We
continue to be confident in the progression of our late-stage pipeline and have
advanced three compounds into registration since our last portfolio
update,” said Ian Read, president of Pfizer’s Worldwide Biopharmaceutical
Businesses. “We have a strong pipeline with programs in development across
important therapeutic areas including oncology, neuroscience and inflammation.
We remain committed to growing our biologics and vaccines development
programs.” “Building on the rapid integration of Pfizer and Wyeth,
the new Pfizer brings a wealth of scientific approaches and technologies to our
key investment areas, and we are developing novel product candidates across all
phases of development,” said Mikael Dolsten, MD, PhD, president of
Pfizer’s Worldwide Research and Development. “We are leveraging the best
product assets of our legacy organizations and driving important steps forward
in strategy and method to deliver a portfolio of next generation medicines and
vaccines.” Pfizer now has 118 programs in Phase 1 through registration,
compared to 133 programs at its last pipeline update in January, 2010. This reflects
25 programs that are new or have advanced along the pipeline and 31 programs
that have been discontinued since the last update.

The current pipeline includes 26 programs in Phase 3 and
nine programs in registration, as well as 27 biologics and four vaccines across
all phases of development.

 

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE